Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
about
Development of selective androgen receptor modulators (SARMs).Inadequacy of Body Weight-Based Recommendations for Individual Protein Intake-Lessons from Body Composition Analysis.Cancer-induced muscle wasting: latest findings in prevention and treatment.The long and winding road for selective androgen receptor modulators.Clinical relevance of sarcopenia in chronic kidney disease.Weight loss versus muscle loss: re-evaluating inclusion criteria for future cancer cachexia interventional trials.Sarcopenia in gastric cancer: when the loss costs too much.Understanding tumor anabolism and patient catabolism in cancer-associated cachexiaResearch priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia.Amelioration of sexual behavior and motor activity deficits in a castrated rodent model with a selective androgen receptor modulator SARM-2f.Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study.Overcoming obstacles in the design of cancer anorexia/weight loss trials.Sarcopenia Predicts Prognosis in Patients with Newly Diagnosed Hepatocellular Carcinoma, Independent of Tumor Stage and Liver Function.Cancer cachexia: Are we ready to take a step forward?Wasting away: How to treat cachexia and muscle wasting in chronic disease?Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models.Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT).Analytical strategies to detect enobosarm administration in bovines.Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines.
P2860
Q34558010-FB726629-1E4C-452D-980B-7B61D74143BCQ37628342-03DDBDB4-1C79-4496-8911-2D4764A96D04Q38681113-B0C4FDFC-412A-4FCA-92A3-C5221510E74FQ38722657-0D21F241-EBA6-40AC-B943-20C6A2CAD7ACQ38757331-37CE1BF7-66E5-41C8-9D45-B904C0BB83E1Q38821210-38F04B08-2E1B-4016-8450-BC09B0182863Q39287062-F99AEBA2-1F41-4F47-89E6-FBB1F166FC84Q39339489-773FEA36-C225-46D0-9947-8B540F398A26Q46621430-88E22EE5-1163-4AD0-A6C7-9952EFE97270Q47127192-31AC3AC3-9E5F-47DA-82DC-2F1D22DEFD24Q47137154-4760781F-80CA-4557-A393-B6B02B2F60F0Q47194265-67BE31C1-E23F-4C24-B36A-465867367112Q47648052-849AFCE8-1D4E-436F-932A-05B9C333F0C4Q48181105-9428F16C-F09D-4D6B-A009-1A9D2ACAF8E8Q48743369-F01CFB53-C079-4B99-B6E2-FE58DB1E316DQ49203044-23905A7A-9B1C-4F4C-B8E0-15F9FF717A84Q50126290-C40B6AB5-CCDE-41B5-A25D-C381EDCCF1DAQ51071369-5D8395BA-F264-4329-876E-3FF1FC215216Q55196969-D39A10C1-E41B-45A9-ACFC-A826CA245081
P2860
Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@ast
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@en
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@nl
type
label
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@ast
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@en
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@nl
prefLabel
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@ast
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@en
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@nl
P2093
P2860
P921
P3181
P1476
Study Design and Rationale for ...... Cancer Patients (POWER Trials)
@en
P2093
Carla M M Prado
Jeffrey Crawford
Mary Ann Johnston
Michael L Hancock
Richard J Gralla
Ryan P Taylor
P2860
P2888
P3181
P356
10.1007/S11912-016-0522-0
P407
P5008
P577
2016-06-01T00:00:00Z
P6179
1017201094